Skip to main content

PURE Bioscience, Inc.

corporate_fare Company Profile

PURE Bioscience, Inc.

PURE·OTC·Industrial Applications And Services·CIK 0001006028

The company develops and sells specialized antimicrobial products to address health and environmental issues related to pathogen and hygiene control. Its technology platform uses patented stabilized ionic silver, with initial products containing Silver Dihydrogen Citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent available in liquid form and various concentrations, known for its effectiveness, low toxicity, non-causticity, and resistance to bacterial development. The company's SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency (EPA), the United States Food and Drug Administration (FDA), and Health Canada. Beyond manufacturing and distributing these products, the company also supplies SDC-based formulations as raw material ingredients for personal care products. Key offerings include PURE® Hard Surface, a food contact surface sanitizer and disinfectant for restaurant chains, food processors, and transportation companies, and PURE Control®, a direct food contact processing aid. The company sells products directly to end-use customers and through third-party distributors across various industries. SDC is an electrolytically generated source of stabilized ionic silver, which is colorless, odorless, tasteless, and non-caustic. The company produces and markets pre-formulated, ready-to-use products, as well as SDC concentrate for use as an additive or raw material. SDC is a stabilized silver ion complex with a shelf life of several years.

PURE Bioscience, Inc. (OTC:PURE) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 8 items for PURE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-15, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for PURE spans 10-Q, 8-K.

Recent high-impact activity:

  • PURE Bioscience Q3 Net Loss Widens to $624K on $506K Revenue
  • PURE Bioscience Reports Increased Q3 Loss, Raises $1M in Dilutive Private Placement, and Authorizes 92% More Shares
  • PURE Bioscience Reports Q3 Results with Surging Current Debt and CEO Transition
  • PURE Bioscience Secures $1.0M in Dilutive Private Placement at Discounted Price
  • PURE Bioscience Secures $1.0M Private Placement, Directors Invest Heavily Amidst Going Concern Warning

Financial Snapshot

Fiscal year ended July 31, 2025
Revenue
$2.2M
Net Income
-$2.4M
Diluted EPS
-$0.02
Op. Cash Flow
-$2.02M
Gross Profit
$1.3M
Operating Income
-$2.27M
Cash & Equivalents
$334K
Debt / Equity
0.00×
Net Margin
-109.1%
Shares Outstanding
111.89M sh
Source: 10-K · filed 2025-10-29 · accession 0001493152-25-020065

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 16,734 shares in PURE as of the September 15, 2026 settlement, a 9.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 20.1% of PURE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)16,734 shares as of September 15, 2026
Change vs prior period▲ 9.0%
Days to cover1.00 at avg daily volume of 58,121
Daily short volume (FINRA facilities)20.1% of 14,303 shares on October 2, 2026
5-day average short volume19.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for PURE, detected from its recent SEC filings · based on capital-structure filings through 2026-06-15.

Going Concern Warning · Massive Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$0.0621 -0.01% today
52-week range · as of 2026-06-15 $0.0386 – $0.2136
Market cap
$8.07M
Volume
14.3K (0.4× avg)
3-mo avg 36.5K
Live data · 2026-10-05 03:36 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PURE - Latest Insights

PURE
Jun 15, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.070
Real-time Price: $0.0621 info
Change: -$0.0079 (-11%) info
Market Cap: $8.074M info
PURE
Jun 15, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.070
Real-time Price: $0.0621 info
Change: -$0.0079 (-11%) info
Market Cap: $8.074M info
PURE
Jun 15, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.070
Real-time Price: $0.0621 info
Change: -$0.0079 (-11%) info
Market Cap: $8.074M info
PURE
May 05, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.067
Real-time Price: $0.0621 info
Change: -$0.0049 (-7%) info
Market Cap: $8.074M info
PURE
May 05, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.067
Real-time Price: $0.0621 info
Change: -$0.0049 (-7%) info
Market Cap: $8.074M info
PURE
Mar 16, 2026, 9:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.080
Real-time Price: $0.0621 info
Change: -$0.0179 (-22%) info
Market Cap: $8.074M info
PURE
Mar 16, 2026, 9:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.080
Real-time Price: $0.0621 info
Change: -$0.0179 (-22%) info
Market Cap: $8.074M info
PURE
Feb 20, 2026, 4:49 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.05672
Real-time Price: $0.0621 info
Change: +$0.00538 (+9%) info
Market Cap: $8.074M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets